- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05488327
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
August 3, 2022 updated by: Lihua Duan, Jiangxi Provincial People's Hopital
Safety and Efficacy of Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
The goal of this study is to evaluate the efficacy and safety of lenalidomide in the treatment of patients with active cutaneous DM.
Study Overview
Detailed Description
Dermatomyositis (DM) are systemic immune-mediated inflammatory diseases which commonly affected the skin and musculoskeletal system.
The cutaneous manifestations of DM are the most important aspect of this disease.
Treatment of these cutaneous manifestations is challenging and currently no universally effective drugs exists.
Lenalidomide, a second-generation derivative of thalidomide, has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator.
Reports on refractory cutaneous manifestations of systemic lupus erythematosus have been mostly performed.
The clinical trials of lenalidomide for cutaneous DM are lacking.
This is a single-centre, prospective, open-label, single-arm study with Lenalidomide 5mg/day added to the background treatment of GCs and immunosuppressants in DM to evaluate the efficacy and safety of lenalidomide in the treatment of cutaneous DM.
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lihua Duan, MD
- Phone Number: 0791-86895639
- Email: lh-duan@163.com
Study Contact Backup
- Name: Jiao Luo, MD
- Phone Number: 0791-86895639
- Email: luojiao02@163.com
Study Locations
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant、non-nursing female.
- Age 18 to 75 years at the time of signing informed consent.
- Fulfilling 2017 ACR/EULAR IIMs classification criteria for DM or ADM.
- Disease activity with skin damage (CDASI ≥12) despite treatment with corticosteroids, immunosuppressive agents or biologics for more than 3 months.
- Written informed consent obtained before taking part in the study.
Exclusion Criteria:
- Pregnant women or breastfeeding mothers, Male and female patients with recent fertility requirements.
- Skin and mucosal lesions should exclude erythema multiforme, syphilis, Sweet disease, Stevens-Johnson syndrome, acne vulgaris, herpes simplex infection, periodic granulocytopenia, and acquired immunodeficiency.
- Severe Concomitant disease: including heart failure (≥level Ⅲ, NYHA), respiratory failure, myelosuppression (WBC<3.0×109/L or N<1.5×109/L, HGB≤85g/L, PLT<100×109/L), peripheral neuropathy.
- Acute severe infections such as sepsis and cellulitis, active hepatitis B or C virus infection, active tuberculosis, and history of a positive test for, or any clinical suspicion of, human immunodeficiency virus (HIV).
- Patients with risk factors for myocardial infarction (including a history of thrombosis), hypercoagulability, or with history of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
- Patients with allergies or contraindications to lenalidomide or thalidomide.
- Uncontrolled or rapidly progressive myositis or interstitial lung disease at the discretion of the investigator which is likely to warrant escalation in therapy beyond permitted background medications.
- Recurrent or chronic bacterial, viral, fungal, mycobacterial, or other infections including HIV.
- History of recurrent herpes zoster, disseminated (multi-dermatomal) herpes zoster, disseminated herpes simplex or ophthalmic zoster. Herpes zoster lesions within 90 days prior to screening.
- Primary or secondary immunodeficiency.
- Current uncontrolled renal, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease, which, in the opinion of the investigator, might place the patient at unacceptable risk for participation in this study.
- History of alcohol, drug, or chemical abuse within one year prior to signing the informed consent form.
- Major surgery within 8 weeks prior to Screening or planned major surgery at any time during participation in the study.
- Immunization with a live/attenuated vaccine within 4 weeks prior to Screening.
- History of malignant tumor within 5 years prior to screening (stable disease for more than 6 months after completion of tumor treatment program can be enrolled).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention with lenalidomide
All subjects will be treated with lenalidomide 5mg/day.
|
All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cutaneous Disease Activity Severity Index (CDASI) activity score
Time Frame: 24 weeks
|
Change in Cutaneous Disease Activity Severity Index (CDASI) activity score (0-100), higher scores mean a worse outcome
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cutaneous Disease Activity Severity Index (CDASI) activity score
Time Frame: 12 weeks
|
Change in Cutaneous Disease Activity Severity Index (CDASI) activity score (0-100), higher scores mean a worse outcome
|
12 weeks
|
International Myositis Assessment & Clinical Studies Group (IMACS) Disease Activity Core Set Measures
Time Frame: 12 weeks and 24 weeks
|
Change in International Myositis Assessment & Clinical Studies Group (IMACS) Disease Activity Core Set Measures
|
12 weeks and 24 weeks
|
SF-36
Time Frame: 12 weeks and 24 weeks
|
Change in SF-36
|
12 weeks and 24 weeks
|
Dermatology Life Quality Index (DLQI)
Time Frame: 12 weeks and 24 weeks
|
Change in Dermatology Life Quality Index (DLQI)
|
12 weeks and 24 weeks
|
Adverse event
Time Frame: 24 weeks
|
Adverse event monitoring
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lihua Duan, MD, Jiangxi Provincial People's Hopital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2022
Primary Completion (Anticipated)
August 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
July 28, 2022
First Submitted That Met QC Criteria
August 3, 2022
First Posted (Actual)
August 4, 2022
Study Record Updates
Last Update Posted (Actual)
August 4, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Skin Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Polymyositis
- Myositis
- Dermatomyositis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- DLH88086
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatomyositis
-
Istituto Giannina GasliniPediatric Rheumatology International Trials OrganizationCompletedJuvenile DermatomyositisItaly
-
The First Hospital of Jilin UniversityCompletedJuvenile Dermatomyositis
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingDermatomyositis, Adult Type
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingDermatomyositis, Adult TypeChina
-
Tulane UniversityCompletedDermatomyositis, Adult TypeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile DermatomyositisFrance
-
The Hospital for Sick ChildrenCompletedJuvenile DermatomyositisCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingGastric Mucosal Manifestations in Patients With DermatomyositisChina
-
MedImmune LLCCompletedDERMATOMYOSITIS OR POLYMYOSITISUnited States
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance